X
[{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allay Therapeutics Launches with First Clinical Data to Demonstrate Weeks of Pain Relief with Ultra-Sustained Non-Opioid Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Evonik","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No Opioids After Surgery: Evonik Invests in Allay Therapeutics and Supplies Key Technology for Pain Therapy Implants","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allay Therapeutics\u2019 Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Allay Therapeutics
Filters
Companies By Therapeutic Area
Details:
ATX101 is a novel investigational configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty.
Lead Product(s):
Bupivacaine
Therapeutic Area: Neurology
Product Name: ATX101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 11, 2024
Details:
Under the agreement, Maruishi will have the exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, a non-opioid, bupivacaine-based drug product, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.
Lead Product(s):
Bupivacaine
Therapeutic Area: Orthopedics/Orthopedic Surgery
Product Name: ATX-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Maruishi Pharmaceutical
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
December 18, 2023
Details:
ATX-101 is a small product placed directly into the TKA surgical site in a simple, ‘place & go’ manner designed to add minimal extra complexity and time to the procedure.
Lead Product(s):
Bupivacaine
Therapeutic Area: Neurology
Product Name: ATX-101
Highest Development Status: Phase II
Product Type: Small molecule
Recipient:
Evonik
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 13, 2022
Details:
Allay intends to proceed into a Phase 2b study of ATX-101 in total knee arthroplasties (TKA, also called total knee replacements) in the United States.
Lead Product(s):
Bupivacaine
Therapeutic Area: Orthopedics/Orthopedic Surgery
Product Name: ATX-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Arboretum Ventures
Deal Size: $60.0 million
Upfront Cash: Undisclosed
Deal Type: Series C Financing
September 15, 2021
Details:
ATX-101 is a novel configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty.
Lead Product(s):
Bupivacaine
Therapeutic Area: Neurology
Product Name: ATX-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 13, 2021